These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22926639)

  • 21. Targeted agents in ovarian cancer.
    Kristedja TS; Morgan RJ; Cristea M
    Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy as an emerging therapy target for ovarian carcinoma.
    Zhan L; Zhang Y; Wang W; Song E; Fan Y; Li J; Wei B
    Oncotarget; 2016 Dec; 7(50):83476-83487. PubMed ID: 27825125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making the most of every option in the treatment of ovarian cancer.
    du Bois A
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):1. PubMed ID: 27797623
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Anticancer Drugs; 2020 Feb; 31(2):101-109. PubMed ID: 31743133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H; Kigawa J
    Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
    Guler E; Smith DA; Somarouthu B; Gujrathi R; Ramaiya NH; Tirumani SH
    Abdom Radiol (NY); 2020 Mar; 45(3):828-841. PubMed ID: 31396642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
    Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
    Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
    Banerjee S; Kaye SB
    Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory considerations on endpoints in ovarian cancer drug development.
    Balasubramaniam S; Kim GS; McKee AE; Pazdur R
    Cancer; 2017 Jul; 123(14):2604-2608. PubMed ID: 28499075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?
    Dai L; Xia P; Di W
    Cancer Invest; 2014 Mar; 32(3):71-80. PubMed ID: 24499107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucinous ovarian cancer: A therapeutic review.
    Xu W; Rush J; Rickett K; Coward JI
    Crit Rev Oncol Hematol; 2016 Jun; 102():26-36. PubMed ID: 27083591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.
    Mihanfar A; Aghazadeh Attari J; Mohebbi I; Majidinia M; Kaviani M; Yousefi M; Yousefi B
    J Cell Physiol; 2019 Apr; 234(4):3238-3253. PubMed ID: 30317560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
    Sessa C; Del Conte G
    Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
    Liang Z; Lu Z; Zhang Y; Shang D; Li R; Liu L; Zhao Z; Zhang P; Lin Q; Feng C; Zhang Y; Liu P; Tu Z; Liu H
    Curr Cancer Drug Targets; 2019; 19(6):449-467. PubMed ID: 30306870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anal fissures associated with targeted therapies in ovarian cancer.
    Squires J
    Clin J Oncol Nurs; 2009 Dec; 13(6):638-42. PubMed ID: 19948462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMPs in ovarian cancer as therapeutic targets.
    Karam A; Dorigo O
    Anticancer Agents Med Chem; 2012 Sep; 12(7):764-72. PubMed ID: 22292752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis: a promising therapeutic target for ovarian cancer.
    Bamias A; Pignata S; Pujade-Lauraine E
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
    Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
    Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
    Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.